ABBV/ENTA—The new info today is that PEARL-3 (treatment-naive GT1b) hit its secondary endpoints as well as the primary. (PEARL-3 top-line results were reported on 1/31/14: #msg-96618696.)
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”